The Noramco Group, an integrated North American-based API and drug product supply chain product and services provider, is investing $25 million into its Halo Pharma facility in Whippany, New Jersey to establish sterile injectable manufacturing capabilities, including ready-to-use syringe, cartridge, and vial filling. This expansion aims to address critical capacity shortages in the U.S. injectable supply chain and meet the growing demand from pharmaceutical companies seeking reliable domestic...